Dr. Cheng on Phase III Findings of Lenvatinib in HCC

Ann-Lii Cheng, MD
Published: Monday, Jun 26, 2017



Ann-Lii Cheng, MD, Distinguished Professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses the phase III trial of lenvatinib (Lenvima) compared with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

HCC is one of the most difficult-to-treat cancers worldwide and is the second leading cause of cancer death, Cheng explains. In a phase III trial—the first which has shown positive findings in 10 years—lenvatinib was compared with the standard of care, sorafenib.

Lenvatinib was found to be associated with tumor shrinkage, prolonged duration of disease control, and an improvement in quality of life.


Ann-Lii Cheng, MD, Distinguished Professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, National Taiwan University College of Medicine, discusses the phase III trial of lenvatinib (Lenvima) compared with sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

HCC is one of the most difficult-to-treat cancers worldwide and is the second leading cause of cancer death, Cheng explains. In a phase III trial—the first which has shown positive findings in 10 years—lenvatinib was compared with the standard of care, sorafenib.

Lenvatinib was found to be associated with tumor shrinkage, prolonged duration of disease control, and an improvement in quality of life.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x